Ewing's sarcoma: ten-year experience with adjuvant chemotherapy

Area of Science:

• Oncology
• Pediatric Oncology
• Skeletal System Neoplasms

Background:

• Ewing's sarcoma is a rare bone cancer primarily affecting children and young adults.
• Treatment historically involved surgery and/or radiation therapy, with limited success in preventing distant metastasis.

Purpose of the Study:

• To evaluate the efficacy of adjuvant combination chemotherapy in improving survival rates for patients with primary Ewing's sarcoma.
• To assess the impact of different chemotherapy protocols and treatment modalities on disease-free survival.

Main Methods:

• A retrospective analysis of 67 consecutive patients with primary Ewing's sarcoma treated with adjuvant chemotherapy (CT) alongside radiation therapy (RT) or surgery.
• Comparison of three chemotherapy protocols (T-2, T-6, T-9) and evaluation of outcomes based on tumor location, patient demographics, and local treatment modality.

Main Results:

• An overall disease-free survival rate of 79% was observed across all patients.
• Patients with distal lesions (95%) had higher survival rates than those with axial (65%) or proximal (79%) lesions.
• Combination CT, especially when administered prior to RT or surgery, demonstrated significant tumor size reduction and facilitated bone healing, improving local control and tolerance to aggressive treatment.

Conclusions:

• Adjuvant combination chemotherapy is a critical component in improving survival for Ewing's sarcoma.
• Early and aggressive CT, integrated with local therapies, enhances both survival rates and local tumor control.
• The findings support the current protocol (T-9) utilizing continuous combination CT for optimal patient outcomes.